Share This Page
Drugs in ATC Class A10B
✉ Email this page to a colleague
Subclasses in ATC: A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10B Market Analysis and Financial Projection
The ATC Class A10B, encompassing blood glucose-lowering drugs excluding insulins, represents a critical segment of the diabetes treatment market, driven by rising global diabetes prevalence and innovations in therapeutic options. Below is an analysis of its market dynamics and patent landscape:
Market Dynamics
Market Size and Growth
- The global non-insulin diabetes therapies market was valued at $17.17 billion in 2023 and is projected to reach $28.04 billion by 2032, growing at a CAGR of 5.6% (source 13). Key drivers include:
- Increasing diabetes prevalence: Over 642 million people are expected to have diabetes by 2040, with Type 2 diabetes accounting for ~90% of cases (source 13).
- Shift toward oral medications: Patients favor non-insulin drugs like metformin, DPP-4 inhibitors, and SGLT2 inhibitors due to convenience and fewer side effects (source 12, 15).
- Innovations in drug classes: GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors (e.g., ertugliflozin) are gaining traction for their efficacy in glycemic control and cardiovascular benefits (source 17).
Key Trends
- New Drug Approvals: Recent FDA approvals, such as once-weekly GLP-1 analogs (source 14) and oral insulin combinations (source 11), are expanding treatment options.
- Commoditization Pressures: While demand for non-insulin therapies rises, price competition is intensifying as payers view these drugs as interchangeable generics (source 3).
- Regional Growth: North America dominates the market (source 12), but Asia-Pacific is emerging rapidly due to high diabetes rates in India and China (source 17). In Iran, despite high diabetes prevalence, utilization remains low, highlighting unmet needs (source 10).
Challenges
- Regulatory hurdles: Strict approval processes for novel delivery methods (e.g., inhalable insulin) delay market entry (source 5).
- Cost barriers: Newer drugs (e.g., GLP-1 analogs) cost ~$492/month versus $5–9/month for older therapies like sulfonylureas (source 17).
- Patent expirations: Generics for drugs like sitagliptin (DPP-4 inhibitor) are entering markets in India and Pakistan, reducing prices (source 18).
Patent Landscape
Key Innovations
- Oral Drug Delivery: Oramed Pharmaceuticals secured a U.S. patent for oral GLP-1 and insulin combinations, potentially revolutionizing administration (source 11).
- Continuous Glucose Monitoring: Dexcom holds patents integrating CGM data with non-insulin therapies to trigger dose adjustments (source 4).
- Combination Therapies: Patents for fixed-dose combinations (e.g., SGLT2 + DPP-4 inhibitors) aim to improve adherence (source 18).
Expiring Patents and Generics
- SGLT2 Inhibitors: Canagliflozin’s compound patent expired in 2024, with generics expected in low- and middle-income countries (source 18).
- GLP-1 Analogs: Liraglutide’s patents expired in China and Japan (2023), with biosimilars likely to reduce costs (source 19).
Competitive Landscape
- Major players include Novo Nordisk, Merck, and AstraZeneca, which dominate with branded drugs like Ozempic (source 14).
- Strategic Moves: Companies increasingly focus on combination therapies and digital health integrations (e.g., smart insulin pens) to differentiate products (source 12, 15).
Future Outlook
- Cost-Effective Solutions: Generics and biosimilars will enhance access but pressure profit margins.
- Technological Integration: Partnerships between pharma and tech firms (e.g., CGM-linked therapies) could redefine treatment protocols.
- Emerging Markets: Africa and South Asia present growth opportunities, but require infrastructure investments and patient education (source 10).
The non-insulin diabetes market is evolving from a high-growth niche to a mature, competitive sector. Success hinges on balancing innovation with affordability.
(Sources: 3, 12, 17, 18)
Key Takeaways
- Market Growth: Driven by diabetes epidemics and drug innovation, but tempered by pricing pressures.
- Patent Shifts: Expirations enable generics, while new patents focus on delivery and combo therapies.
- Regional Gaps: North America leads, but Asia-Pacific and Africa offer untapped potential.
References
- https://www.stocktitan.net/news/ATEN/a10-networks-inc-announces-proposed-offering-of-200-million-of-0q1zqu8z7ngz.html
- https://www.e-fi.de/fileadmin/Assets/Studien/2010/StuDIS_09_2010.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2769893/
- https://patents.justia.com/patents-by-us-classification/600/365
- https://www.precedenceresearch.com/non-injectable-insulin-market
- https://atcddd.fhi.no/atc_ddd_index/?code=A10B&showdescription=yes
- https://simplywall.st/stocks/us/software/nyse-aten/a10-networks/news/what-is-a10-networks-incs-nyseaten-share-price-doing-2
- https://www.phytojournal.com/archives/2017/vol6issue6/PartAB/6-4-459-612.pdf
- https://www.brattle.com/wp-content/uploads/2017/10/7798_expert_report_of_coleman_bazelon_on_behalf_of_nortel_networks_u.k_pension_claimants.pdf
- https://bmjopen.bmj.com/content/4/10/e005859
- https://oramed.com/oramed-granted-u-s-combination-therapy-patent-for-oral-glp-1-insulin-for-the-treatment-of-diabetes/
- https://www.renub.com/diabetes-drug-market-p.php
- https://www.marketdataforecast.com/market-reports/non-Insulin-diabetes-therapies-market
- https://www.pharmiweb.com/press-release/2022-07-21/non-insulin-therapies-for-diabetes-market-key-trends-end-user-types-applications-countries-forecast-to-2022-2030
- https://sites.google.com/view/crafted-legacy/home/trending-report/non-insulin-anti-diabetes-drugs-market-by-applications-by-type-by-end-use
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6556973/
- https://www.coherentmarketinsights.com/market-insight/non-insulin-therapies-for-diabetes-market-2042
- https://medicinespatentpool.org/uploads/2020/04/Chapter-4-Patented-medicines-that-the-WHO-Expert-Committee-considered-as-having-relevant-clinical-benefits-but-needing-additional-data-Case-study-on-novel-medicines-for-type-2-diabetes.pdf
- https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a18_glp-1-ra.pdf?sfvrsn=af9d9573_2
More… ↓
